Skip to main navigation
Search
Deciphera Pharmaceuticals, Inc.

main-navigation

  • About Us
    • Overview
    • Management
    • Board of Directors
    • Advisors
  • Our Pipeline
    • Overview
    • Ripretinib (DCC-2618)
    • Rebastinib
    • DCC-3014
  • Our Focus on Patients
    • Our Focus on Patients and Families
    • Gastrointestinal Stromal Tumors (GIST)
    • Systemic Mastocytosis
    • Breast Cancer
    • Tenosynovial Giant Cell Tumors (TGCT)
  • Our Research
    • Kinases in Cancer
    • Our Kinase Switch Control Platform
    • Presentations & Publications
  • Our Workplace
    • Our Culture and Values
    • Join our Team
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Press Releases
    • Deciphera in the News
    • Events & Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • FAQs
      • Contact IR
      • Email Alerts
  • Contact

Investors
»

ir-nav

  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Analyst Coverage
  • Press Releases
  • Deciphera in the News
  • Events & Presentations
  • Financial Information
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
  • Investor Resources
    • FAQs
    • Contact IR
    • Email Alerts

SEC Filing Details

SEC Filing Details

Document Details

Form
3
Filing Date
Sep 20, 2018
Document Date
Sep 18, 2018
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Deciphera Pharmaceuticals, Inc.
Issuer
Deciphera Pharmaceuticals, Inc
Filer
Martin Daniel C.

Filing Formats

View HTML
Download PDF
Download DOC

toolkit

  • Print

    Print

  • Email

    Email

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Contact IR

    Contact IR


© 2019 Deciphera Pharmaceuticals, Inc. Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.

footer-nav

  • Terms of Use
  • Privacy Policy

main-navigation

  • About Us
    • Overview
    • Management
    • Board of Directors
    • Advisors
  • Our Pipeline
    • Overview
    • Ripretinib (DCC-2618)
    • Rebastinib
    • DCC-3014
  • Our Focus on Patients
    • Our Focus on Patients and Families
    • Gastrointestinal Stromal Tumors (GIST)
    • Systemic Mastocytosis
    • Breast Cancer
    • Tenosynovial Giant Cell Tumors (TGCT)
  • Our Research
    • Kinases in Cancer
    • Our Kinase Switch Control Platform
    • Presentations & Publications
  • Our Workplace
    • Our Culture and Values
    • Join our Team
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Press Releases
    • Deciphera in the News
    • Events & Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • FAQs
      • Contact IR
      • Email Alerts
  • Contact